INCR
InterCure Ltd.
Healthcare — Drug Manufacturers - Specialty & Generic
InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.
None
$5.38
+$0.11 (+2.05%)
Price History
52-Week Range
Sign in to add INCR to a watchlist or set price alerts.
Fundamentals
| Market Cap | $56.97M |
| P/E Ratio (TTM) | - |
| Forward P/E | -0.65 |
| EPS (TTM) | $-0.22 |
| Dividend Yield | - |
| Profit Margin | -13.22% |
| Revenue Growth | 23.90% |
| ROE | -9.27% |
| Debt/Equity | 46.17 |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 51.5 |
| Beta | 0.57 |
| SMA 20 | $0.95 |
| SMA 40 | $0.97 |
| 52-Week High | $1.77 |
| 52-Week Low | $0.68 |
| 50-Day Avg | $0.98 |
| 200-Day Avg | $1.02 |
| Avg Volume | 47.1K |
| Volume | 17.1K |
Performance Analysis
NEUTRALINCR presents a mixed picture with both positive and negative indicators.
-
Trading near its 52-week high ($1.77), which may indicate limited upside.
~
RSI at 51.5 is in neutral territory.
+
Price is above both the 50-day and 200-day moving averages — strong uptrend.
+
Strong revenue growth of 23.9% year-over-year.
-
Operating at a loss with -13.2% margin.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Aug 01, 2026 05:07 UTC
Back to Screener Export Report